- PATIENT PLANS
- ABOUT US
- CONTACT US
Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.
If you missed the webinar, you can still watch the recording here.
Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar.
Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio.
Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT.
Dr. Belisario Arango covered the following topics:
Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients?
Where is the future of cancer care going?
Healthcare reform is undergoing a wave of radical change and disruptive innovation, with stakeholders transitioning to value-based care delivery models to reduce costs and improve quality of care. At the same time, leveraging advanced technologies, experimenting with various business models, and developing new relationships are changing the way that medicine is practiced.
Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together.
We continue to support you and your loved ones by sharing new savings.
The American Turkish Society is pleased to announce the sixth class of "Young Society Leaders," a group of 25 accomplished professionals with a demonstrated record of leadership ability and commitment to serve the U.S.-Turkish community at large.
As a major clinical trial in cardiology nears completion it has provoked a storm of criticism and controversy.
Data released today from a large multi-center study provides a view into the effectiveness of two drugs used to prevent heart problems resulting from breast cancer treatment.
Researchers at Rice University have developed a slow-release hydrogel embedded with immunotherapy drugs, which targets cancer over an extended period.
From age 50 on, most people are advised to get a colonoscopy every 10 years to screen for colon cancer. But others may need to start screening earlier due to certain risk factors, an expert says.
Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.
Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. Since the combined frequency of BRCA1 and BRCA2 mutations exceeds 2 percent among Ashkenazi Jews, we were able to estimate the risk of cancer in a large group of Jewish men and women from the Washington, D.C., area.
This activity is designed to inform physicians about the current availability and use of targeted therapies and precision medicine in gastric (GC) and other gastrointestinal (GI) cancers.
Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day.